Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Figure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
View through CrossRef
<p>CRISPR-mediated <i>KDM4C</i> deletion attenuates PDAC growth <i>in vitro</i> and <i>in vivo</i>. <b>A,</b> Western blot showing <i>KDM4C</i> depletion in selected AsPC1 and KPC-mT4 <i>KDM4C</i>-null clones. <b>B,</b> Colony formation assay (CFA): representative wells comparing AsPC1 cells to <i>KDM4C</i> KO isogenic cells show reduced colony formation ability in the absence of KDM4C. <b>C,</b> Quantification of CFA by ImageJ shows a significant reduction in the number of colonies in <i>KDM4C</i> KO cells compared with <i>KDM4C</i> WT cells; <i>P</i> value was determined by one-way ANOVA test; *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01. <b>D,</b> Proliferation assay measured through % confluence over time by the Incucyte Live Imaging system shows decreased proliferation in the absence of KDM4C, <i>P</i> value determined by one-way ANOVA test. <b>E,</b> Kaplan–Meier survival plot showing increased survival of B6 mice orthotopically transplanted with <i>KDM4C</i> KO KPC-mT4 cells compared with those transplanted with <i>KDM4C</i> WT KPC-mT4 (<i>n</i> = 6 per arm).</p>
American Association for Cancer Research (AACR)
Title: Figure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Description:
<p>CRISPR-mediated <i>KDM4C</i> deletion attenuates PDAC growth <i>in vitro</i> and <i>in vivo</i>.
<b>A,</b> Western blot showing <i>KDM4C</i> depletion in selected AsPC1 and KPC-mT4 <i>KDM4C</i>-null clones.
<b>B,</b> Colony formation assay (CFA): representative wells comparing AsPC1 cells to <i>KDM4C</i> KO isogenic cells show reduced colony formation ability in the absence of KDM4C.
<b>C,</b> Quantification of CFA by ImageJ shows a significant reduction in the number of colonies in <i>KDM4C</i> KO cells compared with <i>KDM4C</i> WT cells; <i>P</i> value was determined by one-way ANOVA test; *, <i>P</i> ≤ 0.
05; **, <i>P</i> ≤ 0.
01.
<b>D,</b> Proliferation assay measured through % confluence over time by the Incucyte Live Imaging system shows decreased proliferation in the absence of KDM4C, <i>P</i> value determined by one-way ANOVA test.
<b>E,</b> Kaplan–Meier survival plot showing increased survival of B6 mice orthotopically transplanted with <i>KDM4C</i> KO KPC-mT4 cells compared with those transplanted with <i>KDM4C</i> WT KPC-mT4 (<i>n</i> = 6 per arm).
</p>.
Related Results
Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>Proximity labeling identifies histone acetylase SIRT1 as a direct KDM4C nuclear interactor and a novel KDM4C–SIRT1–DUSP2 axis regulating ERK activity in PDAC. <b>A,&...
Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract
Deregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC), occurring via both genomic and non-genomic m...
Data from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Data from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<div>Abstract<p>Deregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is one of ...
Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>Compensatory upregulation of KDM4A restores cell-intrinsic ERK signaling in <i>KDM4C</i>-null cells but not immune surveillance. <b>A,</b> Western ...
Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>KDM4C is differentially upregulated in pancreatic cancer and correlates with poor prognosis. <b>A,</b> Western blots show human PDAC cell lines overexpress KDM...
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract
KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found i...
Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract
Background
Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
Abstract
KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC) but targeting mutant KRAS is still challenging. Kinase inhibitors are ideal targeted therapeut...